» Articles » PMID: 35440880

Immunomodulatory Effect and an Intervention of TNF Signalling Leading to Apoptotic and Cell Cycle Arrest on ORL-204 Oral Cancer Cells by Tiger Milk Mushroom,

Overview
Specialty Biotechnology
Date 2022 Apr 20
PMID 35440880
Authors
Affiliations
Soon will be listed here.
Abstract

Research Background: Tiger milk mushroom () is a medicinal mushroom that is geographically distributed in the region of South China, Thailand, Malaysia, Indonesia, Philippines and Papua New Guinea. Consumption of its sclerotium has been reported to treat various ailments. However, its anticancer potential towards oral cancer cell lines is yet to be determined considering the traditional method of its consumption by biting/chewing of the sclerotium.

Experimental Approach: Mushroom sclerotial powder of cultivar TM02® was extracted and fractionated in a chromatographic column prior to cytotoxicity testing against a panel of human oral cancer cell lines. The capability of the identified bioactive fraction in regulating several molecules associated with its tumour necrosis factor (TNF) pathway was investigated.

Results And Conclusions: 2,5-Diphenyl-2H-tetrazolium bromide (MTT) proliferation assay indicated that cell lines ORL-48 (derived from gingiva), ORL-188 (derived from the tongue) and ORL-204 (derived from buccal mucosa) were inhibited by cold water extract of sclerotia and its high-molecular-mass fraction (HMM) in varying degrees with ORL-204 being most affected. Hence, the treatment of ORL-204 with HMM mushroom extract was further investigated. HMM mushroom extract induced apoptosis and G/G phase cell cycle arrest through caspase-3/7 cleavage. Activities of MIP2 and COX-2 were downregulated by 0.2- and 4.6-fold respectively in the HMM mushroom extract-treated ORL-204 cells.

Novelty And Scientific Contribution: Using ORL-204, we showed that HMM mushroom extract may act the TNF pathway at various network sites as a potential dietary compound for cancer prevention and natural adjunct therapeutic to conventional cancer treatment.

Citing Articles

Protective effects of tiger milk mushroom extract (xLr®) against UVB irradiation in DAF-16 anti-oxidant regulation.

Rangsinth P, Sharika R, Sillapachaiyaporn C, Nilkhet S, Chaikhong K, Verma K J Tradit Complement Med. 2025; 15(1):73-83.

PMID: 39807264 PMC: 11725124. DOI: 10.1016/j.jtcme.2024.11.004.


Experimental Models in Unraveling the Biological Mechanisms of Mushroom-Derived Bioactives against Aging- and Lifestyle-Related Diseases: A Review.

Sharika R, Mongkolpobsin K, Rangsinth P, Prasanth M, Nilkhet S, Pradniwat P Nutrients. 2024; 16(16).

PMID: 39203820 PMC: 11357205. DOI: 10.3390/nu16162682.


Fucoxanthin Induces Ferroptosis in Cancer Cells via Downregulation of the Nrf2/HO-1/GPX4 Pathway.

Du H, Wu J, Zhu Y, Hua Z, Jin S, Ji J Molecules. 2024; 29(12).

PMID: 38930897 PMC: 11206433. DOI: 10.3390/molecules29122832.

References
1.
Hamada T, Tsuchihashi S, Avanesyan A, Duarte S, Moore C, Busuttil R . Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. J Immunol. 2008; 180(3):1843-53. PMC: 3589995. DOI: 10.4049/jimmunol.180.3.1843. View

2.
Yap H, Fung S, Ng S, Tan C, Tan N . Genome-based proteomic analysis of Lignosus rhinocerotis (Cooke) Ryvarden sclerotium. Int J Med Sci. 2015; 12(1):23-31. PMC: 4278872. DOI: 10.7150/ijms.10019. View

3.
Yap H, Tan N, Ng S, Tan C, Fung S . Molecular attributes and apoptosis-inducing activities of a putative serine protease isolated from Tiger Milk mushroom () sclerotium against breast cancer cells . PeerJ. 2018; 6:e4940. PMC: 5993024. DOI: 10.7717/peerj.4940. View

4.
Sum A, Li X, Yeng Y, Razif M, Jamil A, Ting N . The Immunomodulating Properties of Tiger Milk Medicinal Mushroom, Lignosus rhinocerus TM02® Cultivar (Agaricomycetes) and Its Associated Carbohydrate Composition. Int J Med Mushrooms. 2021; 22(8):803-814. DOI: 10.1615/IntJMedMushrooms.2020035658. View

5.
Petti S . Lifestyle risk factors for oral cancer. Oral Oncol. 2008; 45(4-5):340-50. DOI: 10.1016/j.oraloncology.2008.05.018. View